時(shí) 間 | Feb 7-8, 2022

地 點(diǎn) | Parsippany, NJ Hilton

屆時(shí)，美迪西國(guó)際研發(fā)服務(wù)部執(zhí)行副總裁戴學(xué)東博士將進(jìn)行PROTAC相關(guān)的主題演講分享。

戴學(xué)東博士 美迪西國(guó)際研發(fā)服務(wù)部執(zhí)行副總裁

美國(guó)麻省理工大學(xué)有機(jī)化學(xué)博士，博士后，深耕于中樞神經(jīng)系統(tǒng)疾病、傳染病和腫瘤疾病化學(xué)藥物的研發(fā)20余載，對(duì)藥物發(fā)現(xiàn)過程中包括苗頭化合物的確定及優(yōu)化，以及成功發(fā)展到高質(zhì)量的臨床候選化合物有著深刻的理解和豐富的實(shí)踐經(jīng)驗(yàn)。戴學(xué)東博士參與主持研發(fā)的藥物有已上市藥物，如Horizant?/Regnite?；臨床藥物，如JNJ-75276617；臨床候選化合物，如Arbaclofen Placarbil，XP21279，XP23829等。

ExecutiveVP and Head of IDSU (International Discovery Service Unit) at Medicilon,obtained his Ph.D. in organic chemistry at MIT. He is a senior-level expertwith over 20 years of experience focusing on small molecule drug discovery anddevelopment in CNS, infectious disease, and oncology therapy areas. He has deepunderstanding and practical knowledge of drug discovery process, including leadidentification, optimization, and development of high quality clinicalcandidate molecules. Prior to Medicilon, Dr. Dai worked at Janssen, HDBiosciences, GSK, and Xenoportwith a demonstrated successful track record ofprogram leadership and made significant contributions to medicinal chemistryprograms that led to the marketed drug Horizant?/Regnite? and several otherclinical candidates (JNJ-75276617, arbaclofen placarbil, XP21279, and XP23829).

美迪西國(guó)際研發(fā)服務(wù)部是美迪西一站式生物醫(yī)藥臨床前研發(fā)服務(wù)平臺(tái)的重要組成部分，使命是持續(xù)助力藥企的國(guó)際化，向全球藥物研發(fā)客戶提供高質(zhì)高效高性價(jià)比的合成化學(xué)、藥物設(shè)計(jì)、以及新藥候選化合物服務(wù)，以滿足客戶在臨床前新藥研究的各個(gè)化學(xué)領(lǐng)域的研發(fā)需求，縮短藥物研發(fā)的周期，降低藥物研發(fā)的成本。

目前，美迪西國(guó)際研發(fā)服務(wù)部擁有豐富海外留學(xué)工作背景的管理團(tuán)隊(duì)和實(shí)驗(yàn)人員、世界先進(jìn)水平的合成實(shí)驗(yàn)室、分析實(shí)驗(yàn)室、和配套的高端儀器設(shè)備。為了給客戶提供更優(yōu)質(zhì)的服務(wù)，國(guó)際研發(fā)服務(wù)部緊跟藥物設(shè)計(jì)以及合成的新進(jìn)展和新技術(shù)，如人工智能/機(jī)器學(xué)習(xí)（AI/ML），蛋白降解靶向嵌合體（PROTAC），高活性藥物及抗體藥物偶聯(lián)物（ADC），惰性碳?xì)滏I直接官能團(tuán)化，光致氧化還原反應(yīng)，以及流動(dòng)化學(xué)等。

The mission of Medicilon International Discovery Service Unit is to provide high quality, efficient and cost-effective synthetic chemistry, drug design, and new drug candidate compound services to global pharmaceutical companies.  We are stride to meet the research and development needs of the clients in various chemical fields of pre-clinical new drug research, shorten the cycle of drug R&D, and reduce the cost of drug R&D.

Medicilon International Discovery Service Unit has a management team and lab personnel with a rich background of studying abroad, a world-leading synthesis and analysis laboratory with installed state-of-the-art instruments and equipment.  In order to provide clients with better services, the International Discovery Service Unit keeps up with new developments and new technologies in drug design and synthesis, such as artificial intelligence/machine learning (AI/ML), proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC), direct functionalization of inert carbon-hydrogen bonds, photoredox reactions, and flow chemistry, etc.

美迪西PROTAC藥物發(fā)現(xiàn)技術(shù)平臺(tái)匯總了當(dāng)前流行的熱門的靶標(biāo)蛋白配體；建立了廣泛的熱門靶向蛋白高度親和力小分子及小分子片段化合物庫(kù)（TPSM），廣泛的E3連接酶，高度親和力的小分子及小分子片段（E3SM）；建立了linker系統(tǒng),包括收集大量具有廣泛多樣性的雙官能團(tuán)連接體（BF-Linker）。這些積累的化合物庫(kù)可以幫助快速高效的合成大量高活性PROTAC雙特異性小分子，極大地提高采用PROTAC技術(shù)進(jìn)行的藥物研發(fā)過程。除了快速合成之外，我們同時(shí)建立和完善的PROTAC生物篩選與測(cè)試平臺(tái)，后續(xù)發(fā)展到臨床前所有階段。

Proteolysis Targeting Chimeras (PROTACs) are interesting biology as achemical knock-down approach in a fast and reversible way. Medicilon has established a wide range of popular target proteins withhigh affinity small molecules and small molecule fragment compound libraries, awide range of E3 ligases, and high affinity small molecules and small moleculefragments. We offer these services in any format you like;we can only do the chemical synthesis part for you, only the in vitro and/or invivo part, or we can offer a fully combined package.

美迪西（股票代碼：688202）成立于2004年，總部位于上海，致力于為全球制藥企業(yè)、研究機(jī)構(gòu)及科研工作者提供全方位的臨床前新藥研究服務(wù)。美迪西的一站式綜合服務(wù)以強(qiáng)有力的項(xiàng)目管理和更高效、高性價(jià)比的研發(fā)服務(wù)助力客戶加速新藥研發(fā)進(jìn)程，服務(wù)涵蓋醫(yī)藥臨床前新藥研究的全過程，包括藥物發(fā)現(xiàn)、藥學(xué)研究及臨床前研究。

From its inception in 2004, Shanghai MedicilonInc. (STAR Market stock code: 688202.SH) has been committed to providingcomprehensive research and development (R&D) services to pharmaceuticalcompanies, research institutions, and any organizations working in thepreclinical space, with the primary objective of supporting and acceleratingpharmaceutical, biopharmaceutical R&D worldwide.

聯(lián)系我們：

郵箱：marketing@medicilon.com.cn

電話: +86 (21) 5859-1500（總機(jī)）